Claus, coincidentally, three new bidders-- at different houses than had the .184 bids--have just made bids at .19 and .191, representing about 75,000 shares.
So, while no a big deal, it's interesting. Next trade, when there is one, will be t .191 or above. Also, Claus, much more telling than whether a given trade has slid to the .184 level is that all the asks under . 2298 got cleared out with that last .184 and -186 trades. So, even though trades were at a bid, the shares were overhanging at .21 ask, and are now gone.
Slug, the bid now is .1814. So, yes, good to have no Asks under .2298', but problem is, and has been, small volume of bids, and virtually no support under whatever the top bid happens to be at the moment. For instance, after the bids in the .18s right now we plunge into the abyss of just a few cents bid.
Level 2 continues to reflect a precipice: a few bids at the high bid, and then no decent floor under those.
Amazing numbers on the galactin correlation.
Also, great to have the 100k shares finally gone at both the .21 and now .22 asks.
But, always a bit troubling to have so few shares bid on level II below the high bid, which itself has small numbers. I think that that will be the ultimate marker for us that word of this company has spread sufficiently: that we will have bidding volumes up and down the level II bidding ranges, instead of huge gaps between the high bids and the next supporting bids so many cents underneath.
"In the trial, the results of which were reported in the November 5, 2013 issue of the International Journal of Cardiology, the authors, from four hospitals and university clinics across Spain, further reported that heart failure patients with elevated galectin-3 levels had rates of hospital readmission and fatal events that were 84% higher than those of patients with lower galectin-3 levels (P-value
""This independent clinical research study, conducted with a real world cohort of heart failure patients, further demonstrates the utility of galectin-3 as a sentinel marker for adverse outcomes in heart failure patients after hospital discharge," said Dr. Paul R. Sohmer, President and CEO of BG Medicine, Inc.
In the trial, the results of which were reported in the November 5, 2013 issue of the International Journal of Cardiology, the authors, from four hospitals and university clinics across Spain, further reported that heart failure patients with elevated galectin-3 levels had rates of hospital readmission and fatal events that were 84% higher than those of patients with lower galectin-3 levels (P-value
"Independent Multicenter Trial Demonstrates Utility of BGM Galectin-3(R) Test for Accurately Classifying Risk of Unplanned Hospital Readmissions and Adverse Outcomes in Patients With Heart Failure
WALTHAM, Mass., Nov. 19, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) announced today the publication of results of an independent multicenter clinical research trial in Europe that enrolled 419 heart failure patients and demonstrated that elevated levels of galectin-3 in blood, as measured using the BGM Galectin-3(R) Test, were significantly predictive of unplanned hospital readmissions and fatal events during the 12 month follow-up period of the trial. 
The physicians who led the study reported that the inclusion of galectin-3 testing into the observational trial's hospital discharge risk planning model significantly improved the accuracy with which patient risk upon discharge could be assigned. Galectin-3 testing correctly identified markedly elevated risk among nearly one-quarter (24.3%) of all patients who, without galectin-3 testing, were otherwise inappropriately placed into the lowest risk category at the time of their initial hospital discharge but who went on to be unexpectedly readmitted to hospital or suffer a fatal event (P-value
The problem was going ahead with FDA American trials without the means to pay for it. They should have been working to expand the impact of their CE, find new applications for RG, expand intl sales, without incurring the years of spending $6+ million annually that they didn't have to start with and didn't know how they would generate going forward during and immediately after the trials. Was a mixture of incompetence and stupidity.
As Ariel noted, shocking low international revs. At least in regard to level of intl sales, the old UK Corgenix and intl sales apparatus was working quite well before the deal that set intl sles plunging several years ago. Yes, Corgenix got a lifeline of cash at the time, but as it has turned out, I don't think they've seen the new product development nor, obviously, te intl sales they were expecting.
This quarter's level of intl sales seems inexplicable-- or, the apparent explanation would seem to be a crumbling of the network or complete breach of best efforts by the distributing and sales company.
What the heck does that mean? Was it terminated? Were endpoints achieved.?How tiny was this project that it was already "completed" last quarter, before it was even announced what exactly the project was? Would be nice if I've misunderstood what the company meant. Maybe there will be a part B with Lilly.
OTC Markets Group is experiencing a systems outage. No quoting or trading is taking place in OTCQX, OTCQB and OTC Pink securities at this time.
We will provide more information as it becomes available.
Charles, don't know whether you were making a joke about Health diagnostic labs and same abbreviation for lipo proteins, but in any case your facts are wrong. It is the LDL, low density lipo proteins that are viewed as as a threat ( and contemporary thinking is wanting them definitively under a 100, with preference for around 70 in higher risk individuals). High density lipo proteins ( hdl) are viewed as protective, and naturally occurring higher levels are viewed as good. HDL levels above 50 are viewed as desirable.
From Irish Health website:
"Aspirin ineffective in many heart patients
Aspirin has long been recognised as a drug that can help protect against adverse heart events, such as heart attacks and stroke. However, Irish scientists have discovered the commonly used drug may be ineffective in preventing recurrent heart attacks in as many as one in five people.
Aspirin protects against heart events by reducing the risk of clots developing in blood vessels. It is often taken by people who have already suffered an adverse event, such as a heart attack. These patients are at a higher risk of suffering another heart attack compared to people in the general population.
However research carried out by the Irish Heart Foundation's National Cardiovascular & Stroke Research Network (NCSRN Ireland) found that in 20% of patients taking aspirin as a preventative medicine, it may be ineffective.
The research was carried out in eight hospitals in Dublin, Cork and Galway and involved over 700 patients with heart disease.
It found that patients with the highest risk of an inadequate response to aspirin therapy were younger men - those in their 40s - with diabetes and high blood pressure, who may also be obese and consume high amounts of alcohol.
"The profile of the patients who are not adequately protected are typically men with high blood pressure, overweight and with a high alcohol intake. This group, who are at high risk of recurrent heart attack, are not getting the benefit of a cheap and generally effective therapy," explained lead researcher, Prof Dermot Kenny, of the Royal College of Surgeons in Ireland.
He said that the findings indicate that about 20% of the 700 people in the study ‘are not protected by their existing therapy'.
Commenting on the findings, Dr Angie Brown, medical director of the Irish Heart Foundation, described them as ‘significant'.
"They point to the critical role of clinical research in identifying this ‘at risk' group."
They know of it. I wrote them about it last year. Made a comment on it during recent and past conference calls.
They just seem complacent that Penn study had no detrimental effect, that the truth is understood by existing clients and that Penn has not prejudiced future clients. Hence no need of publicizing Australian and other successive studies.
I vigorously disagree.
While domestic AR sales slow, Corgenix remains oblivious to the benefits of putting cash and PR behind publicizing the strong Perth study which definitively establishes relationship of aspirin in resistance and resultant higher incidents of heart track.
Here's the most recent Internet reference to that study, in a tele management website of oct 2013:
Aspirin resistance increases heart attack risk
By Tele management, | Health | 0 Comments
(TeleManagement) A study shows that patients who don’t respond to aspirin therapy are more likely to have a heart attack.
Aspirin blocks a molecule called thromboxane which helps platelets stick together, forming clots. That’s how aspirin thins the blood. But aspirin works better for some people than others in preventing clot formation, say researchers at the Royal Perth Hospital, in Australia.
They’ve been involved in a big study of heart disease prevention and this has thrown up some new findings on aspirin. It’s well known that regular aspirin can prevent heart attack and stroke in those at risk. Data on over 5,000 patients showed, however, that aspirin varies in its ability to thin the blood and this effect is carried over into a variability in its ability to protect against heart attack.
The patients who had a high level of a thromboxane-related compound in their urine were twice as likely to have a heart attack compared to those with a low level. Having a high level of this compound indicates that aspirin is not blocking thromboxane as effectively as it is if you have a lower level. These patients are termed ‘aspirin resistant’. The study suggests that they may need additional blood-thinning drugs if they are to get full protection against a heart attack.
Ariel, you want to "get gov. out of te way for a while"? You got it--it's closed. How much more "out of the way" do you want it to get? You like it? good for business? Who's the bozo? The president, and Dem. Senators who agreed to the republican less-than-sequester CR , which would suck the life- blood from the steadily recovering economy --which was plummeting toward complete implosion in 2009 when the Dems took over (Repub. Sec. Of Treasury:" we may not have an economy tomorrow" ] ; or is the bozo the House Repubs who shut the gov., despite getting agreement to their destructive spending levels, because they want to impose a new way of reversing legislation ( Obamacare): not by working to get majorities in both houses with either veto- proof majorities or electing Repub. President, but by threatening to take down the gov. of the US, defaulting, unless thy get their way.? Who's the bozo, Ariel?